CYFRA21-1 as a tumor marker in patients with malignant head and neck tumor

Teruhiro Ogawa, Kazunori Nishizaki, Hirohumi Akagi, Hirokazu Tsurusako, Keiko Nishioka, Kazunari Oda, Nobuhiko Kimura

Research output: Contribution to journalArticle

Abstract

It is well known that cytokeratin 19 is particularly abundant in squamous cell carcinoma of the lung. CYFRA21-1 was developed to detect soluble cytokeratin 19 fragment in serum using two specific monoclonal antibodies. We investigated the usefulness of this new marker compared with that of carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) using 52 serum samples from patients with head and neck malignancies. Of 50 cases of head and neck carcinomas, CYFRA21-1 was positive (>2.0ng/ml) in 21 cases (42.0%) while SCC was found in 9 cases and CEA in 8 cases. Therefore CYFRA21-1 was proven to be a more useful tumor marker than SCC or CEA. We analyzed the results statistically, and found that age and site of lesion (larynx) were factors affecting CYFRA21-1 concentration. The serum CYFRA21-1 level was also demonstrated to be independent of the other two markers. However, we could not determine the cut-off level of serum CYFRA21-1.

Original languageEnglish
Pages (from-to)725-730
Number of pages6
JournalPractica Otologica
Volume89
Issue number6
DOIs
Publication statusPublished - Jan 1 1996

Keywords

  • CEA
  • CYFRA21-1
  • Head and neck malignancies
  • SCC
  • Tumor marker

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'CYFRA21-1 as a tumor marker in patients with malignant head and neck tumor'. Together they form a unique fingerprint.

  • Cite this

    Ogawa, T., Nishizaki, K., Akagi, H., Tsurusako, H., Nishioka, K., Oda, K., & Kimura, N. (1996). CYFRA21-1 as a tumor marker in patients with malignant head and neck tumor. Practica Otologica, 89(6), 725-730. https://doi.org/10.5631/jibirin.89.725